Interaction between miR-142-3p and IBDNF/I Val/Met Polymorphism Regulates Multiple Sclerosis Severity

MiR-142-3p has recently emerged as key factor in tailoring personalized treatments for multiple sclerosis (MS), a chronic autoimmune demyelinating disease of the central nervous system (CNS) with heterogeneous pathophysiology and an unpredictable course. With its involvement in a detrimental regulat...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2024-05, Vol.25 (10)
Main Authors: Dolcetti, Ettore, Musella, Alessandra, Balletta, Sara, Gilio, Luana, Bruno, Antonio, Stampanoni Bassi, Mario, Lauritano, Gianluca, Buttari, Fabio, Fresegna, Diego, Tartacca, Alice, Mariani, Fabrizio, Palmerio, Federica, Rovella, Valentina, Ferese, Rosangela, Gambardella, Stefano, Giardina, Emiliano, Finardi, Annamaria, Furlan, Roberto, Mandolesi, Georgia, Centonze, Diego, De Vito, Francesca
Format: Article
Language:English
Subjects:
Development and progression
Genetic aspects
Multiple sclerosis
Neurophysiology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:MiR-142-3p has recently emerged as key factor in tailoring personalized treatments for multiple sclerosis (MS), a chronic autoimmune demyelinating disease of the central nervous system (CNS) with heterogeneous pathophysiology and an unpredictable course. With its involvement in a detrimental regulatory axis with interleukin-1beta (IL1β), miR-142-3p orchestrates excitotoxic synaptic alterations that significantly impact both MS progression and therapeutic outcomes. In this study, we investigated for the first time the influence of individual genetic variability on the miR-142-3p excitotoxic effect in MS. We specifically focused on the single-nucleotide polymorphism Val66Met (rs6265) of the brain-derived neurotrophic factor (BDNF) gene, known for its crucial role in CNS functioning. We assessed the levels of miR-142-3p and IL1β in cerebrospinal fluid (CSF) obtained from a cohort of 114 patients with MS upon diagnosis. By stratifying patients according to their genetic background, statistical correlations with clinical parameters were performed. Notably, in Met-carrier patients, we observed a decoupling of miR-142-3p levels from IL1β levels in the CSF, as well as from of disease severity (Expanded Disability Status Score, EDSS; Multiple Sclerosis Severity Score, MSSS; Age-Related Multiple Sclerosis Severity Score, ARMSS) and progression (Progression Index, PI). Our discovery of the interference between BDNF Val66Met polymorphism and the synaptotoxic IL1β-miR-142-3p axis, therefore hampering miR-142-3p action on MS course, provides valuable insights for further development of personalized medicine in the field.
ISSN:1422-0067
1422-0067
DOI:10.3390/ijms25105253